Bedrijfsoverzicht
Scholar Rock Holding Corporation is a biopharmaceutical entity dedicated to enhancing the quality of life for children and adults suffering from spinal muscular atrophy (SMA) alongside other rare, severe, and debilitating neuromuscular diseases. Operating within the healthcare sector specifically in the biotechnology industry, the company leverages a novel understanding of molecular mechanisms related to growth factor activation to develop targeted therapies. The organization currently employs 289 individuals and holds a substantial market capitalization of $5.74 billion, which positions it as a significant player in the specialized biopharmaceutical landscape. This valuation figure, combined with the absence of reported annual revenue in the provided data, indicates that the company's market value is primarily derived from the potential of its pipeline assets and intellectual property rather than current sales performance, a common characteristic for early-stage or development-focused biotechnology firms.
Financiële gezondheid
The company reports a net income of $-377,939,000 over the trailing twelve months, while its EBITDA stands at $-382,987,000, reflecting a substantial operational loss that is typical for biotechnology entities investing heavily in research and development before product commercialization. Since the provided revenue data is unavailable, the financial analysis relies on these negative income and EBITDA figures, which suggest a cost structure dominated by R&D expenditures and clinical trial expenses rather than sales-related costs. The free cash flow for the period is $-162,622,256, indicating a significant cash outflow that limits immediate financial flexibility but is often necessary to fund the long-term development of novel therapies. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a standard presentation for companies that have not yet generated commercial revenue or where revenues are negligible relative to the massive upfront investment in drug discovery. On the balance sheet, the company holds $367.56 million in cash against $108.92 million in debt, resulting in a debt-to-equity ratio of 44.37, which suggests a leverage profile that is moderate for a cash-burning biotech firm given the substantial cash reserves available to service obligations. The current ratio of 6.95 demonstrates a robust short-term liquidity position, implying that the company possesses ample liquid assets to cover its current liabilities without immediate refinancing needs. Furthermore, the return on equity is -123.1% and the return on assets is -54.7%, metrics that reveal that management effectiveness is currently measured by the ability to preserve capital while advancing clinical programs rather than generating immediate returns on invested capital.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is listed as N/A due to negative earnings, whereas the forward P/E is -23.29, a valuation metric that implies the market expects future earnings to turn positive or that current pricing is based on future revenue potential rather than historical profitability. The price-to-book ratio stands at 22.08, indicating a significant market premium over the company's book value, which reflects investor confidence in the future commercial success of its drug candidates and the scarcity of assets in the biotechnology sector. Alternative valuation metrics such as the price-to-sales ratio, which is N/A, and the EV/EBITDA of -14.31, suggest that traditional multiples are not applicable in their conventional form, requiring analysts to focus on pipeline value and potential market capture rather than current profitability multiples. The stock's price range over the last year fluctuated between a 52-week low of $27.07 and a 52-week high of $51.62, providing a context for volatility and trading bands relative to recent historical performance. The beta value of 0.69 indicates that the stock's price volatility is lower than the broader market, suggesting that the company's stock price is less sensitive to general market fluctuations compared to high-beta technology or small-cap stocks.
Growth & Income
The available facts indicate that revenue growth year-over-year and earnings growth year-over-year are both N/A, which precludes a comparison of growth rates between earnings and revenue as both metrics are currently unavailable or negligible. As the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the firm retains all generated value or cash reserves to reinvest into research and development activities rather than distributing income to shareholders. This reinvestment strategy is standard for biotechnology companies in the development phase, where capital is directed toward clinical trials and regulatory approvals to generate future revenue streams. Consequently, the overall growth and income profile of Scholar Rock Holding Corporation is characterized by a focus on capital preservation and pipeline advancement, with no current income generation from dividends or significant historical revenue growth data to analyze.